A Randomized, Double-blind, Placebo-controlled, Parallel-group, Multicenter Study to Explore Changes in Subcutaneous Adipose Tissue and Modulation of Skin Inflammation After 12 Weeks of Treatment With Secukinumab, Compared to Placebo, and up to 52 Weeks of Treatment With Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis
Phase of Trial: Phase IV
Latest Information Update: 26 Apr 2019
Price : $35 *
At a glance
- Drugs Secukinumab (Primary)
- Indications Plaque psoriasis
- Focus Therapeutic Use
- Acronyms ObePso-S
- Sponsors Novartis Pharmaceuticals
- 18 Apr 2019 Status changed from recruiting to completed.
- 31 Aug 2018 Biomarkers information updated
- 22 Jun 2017 Planned End Date changed from 2 Apr 2019 to 5 Apr 2019.